{"name":"Biolexis Therapeutics","slug":"biolexis-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1tc0wyd2lqaUU2Y2FmVWNqbUFnMF9XWEE5bmtUWm1CSHJhZ0Zyd0RDeUhDRFZIb29GMDQ4UWJKNWFWUWxKeDVZVHBDcWwtN0c2dUgzVVd6Z09ST2htSGV6ZEFRSEN6d2FYbDhTWDNranJXMkZJTmtmRDl3dw?oc=5","date":"2025-10-06","type":"pipeline","source":"pharmaphorum","summary":"6th Age-Related Disease Therapeutics Summit - pharmaphorum","headline":"6th Age-Related Disease Therapeutics Summit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQVFVWZnRMSlNHR3hBb21BbGpETlJIYmJIbHYwXzYwZjJhRVhIckVoOGRvcWZkZXZhZzR0V1ozWldHdlltLXhFZG5SS0Qxb0EyX1R3VXN2bVZRR09lNF9SQkYtUDJvbXFmQTBqWkRscWNsTnZBamh6cV96WVlPdGJ4RUVncThSQ25iVUo2MHRDVi11UXlmNEREWWFQSy1YdmpsaFYwME1LbUhfdWMyV2xSb1ljb1lLM25tNkxhZTRsUFd2VTU4ZlVjLXU5d0pSTUdlUV9XazJJaUljbTJLVDNWYnBuYTdfdDBmZWpialJGZWk?oc=5","date":"2025-06-12","type":"trial","source":"PR Newswire","summary":"Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials - PR Newswire","headline":"Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE40bDFHVnNpWTluT0RMQTIwNmFacEpBcVdmdEp5VGN2Q0k1U1dVOG9HcVpleWgtdzV2NHlQNXEzRTBhdzJiYVdHLVBGTF9scFQ0UFA3a3gxTHM2UWJ3RFlGakJMVTdLaTU1TWJPYVFuaWk5Z1phMVdDUEZUdk8?oc=5","date":"2024-12-12","type":"trial","source":"The Pharma Letter","summary":"Halia touts Phase II success with HT-6184 - The Pharma Letter","headline":"Halia touts Phase II success with HT-6184","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOajNVQzFKUGZtQlJSTG00OTZBQ2tZTTVEeUc5YU04T2NPRmx5TjB2OHFJNUhWOGozUVZNSVBxSGFDbU9fTkdzX0IycjhseHlnNWtKZUJDd09aZXluaEd5VFR6OHBoV2x3T3NreU00NVpEV1pMZkducXNzcWNPaFpsaW44VjJsQ2FVci1pTmdR?oc=5","date":"2024-11-13","type":"trial","source":"Yahoo Finance","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Yahoo Finance","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOZF9HR0cwWTltNmtaWGNhQ0JxbUxDaF8tdWhIZHRYRUg2NkpzUUFReU5MSGRTcy05QU55cFpYZ1VPLS1YV2hWeUdQOXl5dlRwbDNUek5iOUVGU01KSVMyd3k3dkFjeDdDQXgtTDRidlFuNW5UcHJXNHlRRTZSZm1zX0lsYzBfTmJPaWFuUUowaWJIbWxWZE1idHBWak9leWpBLTFzNUdLX18wcjkyaFlfT2JIbkFZTGViTndzSHJZQ3pWX01xeTRCV1hhRTlOQXNwZVVIM1llS1dsLWJwTXRpLW9sbW5MWUV3SmRxR1VESVJ4amJ3THRnTm9OcHdsV1ZsTHlzYjhOU2dCZGpDUkNQT3o2X0d2My1QakpfVTN0X3c4elN1a2FtdnN0ZXk4dw?oc=5","date":"2024-08-06","type":"trial","source":"GlobeNewswire","summary":"Obesity Clinical Trial Pipeline Appears Robust With 80+ Key - GlobeNewswire","headline":"Obesity Clinical Trial Pipeline Appears Robust With 80+ Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxONzBxb0dvQXRRWEFWZUdpZzdMcFJwWFhpZ2U0bDhtbFI2cDBfMFlxVmJtZ1dLUS1pNm1NUXBrNUo4TnNOZHFxOWNETll4bjZfTjFYbTdEckw3eXgxTkMwVGFUQmNYLW1VUXdwYWhseHkyV0JiRGZBekRTN2tXbVVMM1M1NTYyaFNNeEt4d0F1QWxGbmlBN2VjQ1pxdVY4WmozZi1rLXlBVVdvU1hnUWQ3Ry1yNnZjVmptUHAzcTVDczlwWm5JVjRvOQ?oc=5","date":"2024-07-19","type":"pipeline","source":"24-7 Press Release Newswire","summary":"David J. Bearss, PhD Celebrated for Dedication to the Pharmaceutical Industry - 24-7 Press Release Newswire","headline":"David J. Bearss, PhD Celebrated for Dedication to the Pharmaceutical Industry - 24-7 Press Release Newswire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQUlo2Y3N1NTdkWWMtQmpTc1JjOGFSS0hTWXZ5V3hHRTZQUHQ5bzN1NWpETTUwMV85NDJoQURiUFJQVFR4QVRiU3liLTZ0X1lpZFE4TjJMN0l1Y2tlN3psN3d0ai1QZ2s4Q3ZhOVFpZ0RHWGREVklCYWtaSjQwOUZGdjJNbXluZTZMRDJ2cjFnT2pQcUVjelVVTy1tWXFfNmZ6ZTJvU3BHTXRQYTdzR2xUX0FPQkdVV3F0clRpVWZJR2gxRURGTnBmNmJZaXc3Sm1OVkk1ZXRiaW5mQjZPR05Ca0d5OTZjUQ?oc=5","date":"2024-06-21","type":"pipeline","source":"PR Newswire","summary":"Biolexis Therapeutics to Present Two Groundbreaking Abstracts at Upcoming Scientific Conference - PR Newswire","headline":"Biolexis Therapeutics to Present Two Groundbreaking Abstracts at Upcoming Scientific Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNVnE1Q0VZN0Y5X19qMVV4VVRQbVRtYURpaGhkTkZWOHMxSHlCWWhwTFM5OU50WEVYXy1lQ3h1MDNVMTZJUHp3LUZRMjYzMF9DdWpNejc0ejJJek5uX0ZlZF9sOG9TNk9LTjFMSjdXaGdFdmRSTno1R1FXUkI5Qm54YTM4NFo1eHN1VFpjNkc4eWZVam9RdVRRa0xZOWpaQUh5NXBKaG0tN1p2N3hiZkgxN1BvTkQ?oc=5","date":"2024-01-05","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Biotech investment diversifies into cell therapies and immunology - drugdiscoverytrends.com","headline":"Biotech investment diversifies into cell therapies and immunology","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}